Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
10/2003
10/09/2003WO2002060375A3 Diphenyl ether derivatives and their uses as heparanase inhibitors
10/09/2003WO2002059154A3 Neutralizing human monoclonal antibodies against hiv-1, their production and uses
10/09/2003WO2002056905A3 Molecular antigen array
10/09/2003WO2002055063A3 Fumaric acid amides
10/09/2003WO2002040676A3 Mutant allergens
10/09/2003WO2002034284A3 Methods of therapy for hiv infection
10/09/2003WO2002033099A3 Human kinases
10/09/2003WO2002030433A3 Use of stem cells and cd6-depleted stem cells for inducing tolerance of allogenic transplants and/or for treating leukaemia
10/09/2003WO2002026245A3 Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
10/09/2003WO2002016434A9 T CELL RECEPTOR Vβ-Dβ-Jβ SEQUENCE AND METHODS FOR ITS DETECTION
10/09/2003WO2001085917A3 A device
10/09/2003US20030191308 Quinazoline compounds
10/09/2003US20030191291 Synthetic erythropoiesis stimulating proteins
10/09/2003US20030191285 Novel g protein-coupled receptor proteins and dnas thereof
10/09/2003US20030191178 Therapy for vision defects; hypotensive agents; respiratory system disorders
10/09/2003US20030191175 Indole sPLA2 inhibitors
10/09/2003US20030191167 Autoimmune disease, antiarthritic agents, antiallergens, anticancer agents
10/09/2003US20030191160 Aids therapy; calibration efficiency of benzimidazole compound
10/09/2003US20030191155 Triazole derivatives
10/09/2003US20030191148 Macrolides
10/09/2003US20030191122 Antidepressants; Alzheimer's disease; Parkinson's disease; central nervous system disorders
10/09/2003US20030191103 Hormone replacement therapy
10/09/2003US20030191098 Synergistic mixture of thalidomide antiinflammatory agnets
10/09/2003US20030191097 Hormone replacement therapy
10/09/2003US20030191086 Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof
10/09/2003US20030191079 Methods for treating and preventing infectious disease
10/09/2003US20030191076 Induction of immunology response; transgenic plant; measles
10/09/2003US20030191074 Antibody therapy; immobilization
10/09/2003US20030191069 2-oxoquinoline compounds and pharmaceutical uses thereof
10/09/2003US20030191065 Insulin-like growth factor; genetic engineering; central nervous system disorders
10/09/2003US20030191063 Peptide selection method
10/09/2003US20030191052 Infection therapy; binding of mannan lecithin to protein
10/09/2003US20030190687 Interacts with human DR5 to produce agonistic or antagonistic effects including inhibition of cell proliferation and apoptosis; used to treat apoptosis-related disease and unregulated cell growth
10/09/2003US20030190685 Bind to Tumor Necrosis Factor(TNF)-Related Apoptosis Inducing Ligand (TRAIL) receptors ; used in the prevention and treatment of cancers and other proliferative disorders
10/09/2003US20030190642 Thymus expressed human cytochrome p450(p450tec)
10/09/2003US20030190639 Diagnosis of Cryptogenetic inflammatory bowel diseases (IBDs)
10/09/2003US20030190613 Polynucleotide encoding an activated human T-lymphocyte-derived protein related to ubiquitin conjugating enzyme
10/09/2003US20030190368 Identification of cellular activation factors and their use as diagnostic markers
10/09/2003US20030190331 Vaccine composition and stabilisation method
10/09/2003US20030190328 Immuno-reactive peptide CTL epitopes of human cytomegalovirus
10/09/2003US20030190314 Administering spray dried plasma for modulating immunoglobulin levels; vaccines; for weight gain; autoimmune disorders
10/09/2003US20030190311 Immunoglobulins; fusion proteins; vaccines
10/09/2003US20030190309 Novel probiotics for pet food applications
10/09/2003US20030190306 HLA matching donor-originating activated lymphocytes to be used in prevention/treatment of tumors, infectious diseases and autoimmune diseases, treatment method achieved by using the lymphocytes, formula having the lymphocytes as a main constituent thereof, method for manufacturing the formula and preparation kit to be used to prepare the formula
10/09/2003US20030190303 For treating allergic disorders characterized by a local immune response including inflammatory skin reactions, asthma, and arthritis
10/09/2003US20030188740 Method for production of enhanced traceable immunizing drinking water and other liquid and gas products, devices for production and use thereof, and use of the enhanced products for immunizing living beings
10/09/2003CA2480888A1 New aryl imidazoles and related compounds as c5a receptor modulators
10/09/2003CA2480857A1 Improvements in pharmaceutical compositions
10/09/2003CA2480751A1 Tolerogenic antigen-presenting cells
10/09/2003CA2480694A1 Ox40r binding agents
10/09/2003CA2480682A1 Nucleic acid sequence and protein, and polypeptides encoding mannitol dehydrogenases or parts thereof, and their preparation and use in diagnostics and therapy
10/09/2003CA2480679A1 (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors
10/09/2003CA2480661A1 A method of modulating cellular activity
10/09/2003CA2480634A1 Use of statins and other immunomodulatory agents in the treatment of autoimmune disease
10/09/2003CA2480568A1 Thiazol-2-yl-imine compounds as pde-7 inhibitors
10/09/2003CA2480317A1 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
10/09/2003CA2480128A1 Methods of using flt3-ligand in immunization protocols
10/09/2003CA2479939A1 Immunosuppressant compounds, methods and uses related thereto
10/09/2003CA2479912A1 Benzenesulphonate salt of a morpholine urea derivative for use as a ccr-3 antagonist in the treatment of inflammatory conditions
10/09/2003CA2479910A1 N-{ '(2s) -4- (3, 4-difluorobenzyl) morpholin-2yl]methyl} -2-{3-' (methylsulphonyl) amino] phenyl}acetamide as ccr3 antagonist for the treatment of inflammatory conditions
10/09/2003CA2479647A1 Human deubiquitinating protease gene on chromosome 7 and its murine ortholog
10/09/2003CA2479205A1 Azaindoles as inhibitors of c-jun n-terminal kinases
10/09/2003CA2477764A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
10/09/2003CA2477751A1 Combinations of epinastine, belladonna and pseudoephedrine as new pharmaceutical formulations
10/09/2003CA2474512A1 Method for producing pseudo islets
10/09/2003CA2448540A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
10/08/2003EP1350848A2 T-cell membrane protein (TIRC7), gene encoding it and antibodies against it and uses thereof
10/08/2003EP1350798A1 Allergenic protein HEV b III of natural rubber latex, its production and use in assays
10/08/2003EP1350797A1 Allergenic protein Hev b II of natural rubber latex, its production and use in assays
10/08/2003EP1350519A1 Drugs and foods improving the quality of life and process for producing the same
10/08/2003EP1350518A1 Prolonged release of GM-CSF
10/08/2003EP1350514A2 Therapeutic use of cis-element decoys in vivo
10/08/2003EP1350512A1 Combinations of epinastine, belladonna and pseudoephedrine as new pharmaceutical formulations
10/08/2003EP1350509A1 Mucosal immunomodulator and use thereof
10/08/2003EP1350111A2 Detection of allergen-specific ige
10/08/2003EP1350085A2 Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
10/08/2003EP1349939A2 Aminoacyl trna synthetases
10/08/2003EP1349936A2 Regulation of human b7-h2 protein
10/08/2003EP1349930A2 Human proteins, polynucleotides encoding them and methods of using the same
10/08/2003EP1349920A2 Adenylate cyclases
10/08/2003EP1349919A1 Extramedullary adipose tissue cells and use thereof for regenerating hematopoietic and muscular tissues
10/08/2003EP1349873A2 Modulation of il-2- and il-15-mediated t cell responses
10/08/2003EP1349852A2 4-(hetero)aryl substituted indolinones
10/08/2003EP1349842A1 1-dimercaptoalkylquinazolin-2,4(1h,3h)-diones as matrix metalloproteinase (mmp) inhibitors
10/08/2003EP1349841A2 Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
10/08/2003EP1349840A2 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
10/08/2003EP1349836A2 Tetracyclic derivatives as spla2 inhibitors
10/08/2003EP1349832A2 Substituted benzoindoles as spla2 inhibitors
10/08/2003EP1349576A2 Combined use of enzyme inhibitors and pharmaceutical preparations thereof for the treatment and prophylaxis of arteriosclerosis, for the treatment and prevention of allergic reactions of type i according to the gell and coombs classification, and for the treatment and prevention of dermatological di
10/08/2003EP1349568A1 Immunomodulatory constructs and their uses
10/08/2003EP1349553A1 Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain
10/08/2003EP1349550A1 Substituted-4-quinolones
10/08/2003EP1349546A2 Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect
10/08/2003EP1349485A2 Compositions and methods for the therapy and diagnosis of ovarian cancer
10/08/2003EP1227808B1 Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation
10/08/2003EP1214318B1 Imidazo[1,2-a]pyridine and pyrazolo[2,3-a]pyridine derivatives
10/08/2003EP1198464B1 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-i]PURIN-5-ONE DERIVATIVES
10/08/2003EP1181285B1 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides
10/08/2003EP0927170B1 Piperazino derivatives as neurokinin antagonists
10/08/2003EP0566647B1 Improved humanized immunoglobulins
1 ... 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 ... 1172